RGNX (STOCKS)
REGENXBIO Inc.
$8.680000
-0.170000 (-1.92%)
Prev close: $8.850000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Curran M. Simpson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $430.30M
- Employees
- 353
- P/E (TTM)
- -2.44
- P/B (TTM)
- 2.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-1.20 | $-1.33 | +0.1316 | +9.88% |
|
Jun 2025 (Q2)
|
$-1.38 | $-1.12 | -0.2580 | -22.99% |
|
Mar 2025 (Q1)
|
$0.12 | $0.49 | -0.3724 | -75.63% |
|
Dec 2024 (Q4)
|
$-1.01 | $-1.17 | +0.1596 | +13.65% |
Financial Statements
| Revenues | $161.32M |
| Benefits Costs and Expenses | $339.23M |
| Costs And Expenses | $316.25M |
| Nonoperating Income/Loss | -$22.99M |
| Operating Expenses | $282.68M |
| Depreciation and Amortization | $15.77M |
| Research and Development | $219.07M |
| Other Operating Expenses | $47.84M |
| Operating Income/Loss | -$154.93M |
| Income/Loss From Continuing Operations After Tax | -$177.92M |
| Income/Loss From Continuing Operations Before Tax | -$177.92M |
| Net Income/Loss | -$177.92M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$177.92M |
| Net Income/Loss Available To Common Stockholders, Basic | -$177.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.46 |
| Diluted Earnings Per Share | -$3.46 |
| Basic Average Shares | 51,971,000 |
| Diluted Average Shares | 51,971,000 |
| Assets | $525.20M |
| Current Assets | $331.97M |
| Cash | $302.00M |
| Accounts Receivable | $25.35M |
| Prepaid Expenses | $12.94M |
| Noncurrent Assets | $193.24M |
| Fixed Assets | $107.52M |
| Other Non-current Assets | $85.72M |
| Liabilities | $363.75M |
| Current Liabilities | $124.57M |
| Accounts Payable | $22.27M |
| Wages | $15.08M |
| Other Current Liabilities | $87.23M |
| Noncurrent Liabilities | $239.18M |
| Equity | $161.45M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $161.45M |
| Liabilities And Equity | $525.20M |
| Net Cash Flow From Operating Activities | -$103.30M |
| Net Cash Flow From Operating Activities, Continuing | -$103.30M |
| Net Cash Flow From Investing Activities | -$13.13M |
| Net Cash Flow From Investing Activities, Continuing | -$13.13M |
| Net Cash Flow From Financing Activities | $118.62M |
| Net Cash Flow From Financing Activities, Continuing | $118.62M |
| Net Cash Flow | $2.19M |
| Net Cash Flow, Continuing | $2.19M |
| Comprehensive Income/Loss | -$177.99M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$177.99M |
| Other Comprehensive Income/Loss | -$70.00K |